相关实验视频
Updated: Jan 16, 2026

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.5K
乳腺癌患者心脏毒性风险预测模型:多中心前性CHECK HEART-BC研究
Yosuke Terui1, Kotaro Nochioka1, Hideki Ota2
1Department of Cardiovascular Medicine, Tohoku University Graduate School of Public Health, Tokyo, Japan.
JACC. Asia
|October 1, 2025
概括
一个新的风险模型准确地预测乳腺癌患者的化疗诱导心脏毒性. 这种工具有助于早期检测和监测,改善接受癌症治疗的患者的心脏事件的结果.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 医疗成像医学成像
背景情况:
- 早期发现和治疗心脏毒性对于减少癌症患者心脏事件至关重要.
- 目前缺乏一种可靠的化学疗法诱导的乳腺癌患者心脏毒性预测模型.
研究的目的:
- 开发心脏毒性风险预测模型.
- 在接受化疗的乳腺癌患者中建立有效的心脏毒性监测策略.
主要方法:
- 在25个机构对559名化学疗法未经治疗的女性乳腺癌患者进行前性查.
- 心脏毒性定义为左心室喷射分数从基线减少>10%至<53%.
- 使用6个预测变量开发CHECK HEART得分.
主要成果:
- 在平均366天的随访期间,在8.2%的患者中观察到心脏毒性.
- 检查心脏得分包括心率,心脏成像参数和特定的化疗药物 (环素,特拉斯图祖马布).
- 在12个月后,基于治疗前数据的CHECK HEART得分显示了可接受的预测准确性 (AUC:0.82).
结论:
- 多变量风险预测模型准确预测接受化疗的乳腺癌患者的心脏毒性.
- 开发的模型可以支持对心脏毒性的有效监测和管理.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648

